3 Amendments of Henna VIRKKUNEN related to 2020/2071(INI)
Amendment 3 #
A. whereas the problem of medicine shortages in the Member States is getting ever more severe on account of the lack of production capacity in the EU and the relocation of our industries in the sector to other markets in third countries; whereas fostering medical innovation and research in the EU is required to benefit patients and to ensure the EU pharmaceutical industry remains globally competitive;
Amendment 53 #
Draft opinion
Paragraph 4
Paragraph 4
4. Highlights the importance of IT systems in facilitating the exchange of information between the various actors involved in the transport logistics chain, including the customs authorities, with a view to optimising the distribution of medicines in the Member States and planning supply times more efficiently; stresses that medical supply chains can be improved through investments in skills, health data infrastructure, supporting regulatory framework and intellectual property policies that foster innovation;
Amendment 72 #
Draft opinion
Paragraph 7
Paragraph 7
7. Notes that the COVID-19 outbreak has laid bare the weaknesses of the European production system, highlighting the importance of delivering medicines swiftly in urgent and exceptional circumstances that could arise in the future; highlights the importance of R&D investments to ensure that the pharmaceutical industry can respond to tomorrow’s needs.